Combinations of substituted 1-phenyl-1,5-dihydro-pyrido-[3,2-b]indol-2-ones and other HIV inhibitors

The present invention concerns combinations comprising a compound of formula (I) the N-oxides, salts, stereoisomeric forms, racemic mixtures, prodrugs, esters or metabolites thereof, wherein n is 1, 2 or 3; R1 is H, CN, halo, aminoC(-O), C(-O)OH, C1-4alkyloxyC(-O), C1-4alkylC(-O), mono- or di(C1-4alkyl)aminoC(-O), arylaminoC(-O), N-(aryl)-N-(C1-4alkyl)aminoC(-O), methanimidamidyl, N-hydroxy-methanimidamidyl, mono- or di(C1-4alkyl)methanimidamidyl, Het1 or Het2; R2 is H, C1-4alkyl, C2-10alkenyl, C3-7cycloalkyl, wherein said C1-10alkyl, C2-10alkenyl and C3-7cycloalkyl may be optionally substituted; R3 is nitro, cyano, amino, halo, hydroxy, C1-4alkyloxy, hydroxyC(-O), aminoC(-O), C1-4alkyloxyC(-O), mono- or di(C1-4alkyl)aminoC(-O), C1-4alkylC(-O), methanimidamidyl, mono- or di(C1-4alkyl)methanimidamidyl, N-hydroxy-methanimidamidyl or Het1; and another HIV inhibitor. The invention also concerns products comprising a compound of formula (I) and another HIV inhibitor, as a combined preparation for simultaneous, separate or sequential use in treatment of retroviral infections such as HIV infection, in particular, in the treatment of infections with multi-drug resistant retroviruses.